All In Biotech

Drug Trial Radar · NCT07389499

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 2027

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Grit BiotechnologyIndustry
Sponsor type
Industry
Collaborators
Shanghai Zhongshan Hospital
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-arm, open-label, dose-escalation and dose-expansion clinical trial, divided into two phases: the first phase is the dose-escalation phase, and the second phase is the dose-expansion phase. In the dose-escalation phase, approximately 9-18 adult participants with immune-mediated kidney diseases are planned to be enrolled and treated with GT719 universal cell injection. The objectives of this phase are to evaluate the safety and tolerability of the product, determine the recommended dose (RD) for subsequent studies, conduct a preliminary assessment of its clinical efficacy, and investigate the pharmacokinetic and pharmacodynamic characteristics. Upon completion of the dose-escalation phase, after evaluation by investigators and collaborators, an appropriate dose will be selected for the dose-expansion phase. An additional 12 participants will be enrolled to fully assess the safety and efficacy of the product.

Conditions

  • IgA Nephropathy (IgAN)
  • Membranous Nephropathy
  • ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)
  • Refractory Podocytopathy
  • Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

Interventions

  • CD19-targeted iNKT Cell InjectionBiological

    Composed of CD19-targeted iNKT cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability: Evaluate the incidence, correlation with the investigational product, severity, and other relevant aspects of adverse events (AEs) and serious adverse events (SAEs) occurring in participants during the trialTime frame: 24 Months
  2. Changes in vital signs before and after treatmentTime frame: 1 Month
  3. Changes in clinical symptoms before and after treatmentTime frame: 1 Month
  4. Changes in laboratory tests before and after treatmentTime frame: 1 Month
  5. Changes in electrocardiograms before and after treatmentTime frame: 1 Month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.